Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression

Conditions

• Advanced Cancers Associated With Mesothelin Expression

Interventions

• BIOLOGICAL: HPN536 Fixed IV 6 to 560 ng/kg
• BIOLOGICAL: HPN536 1 Prime Step IV 600-1200 ng/kg Target
• BIOLOGICAL: 2 Prime Step IV 900-14000 ng/kg Target

Sponsor

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)